6:07 PM
 | 
Oct 22, 2012
 |  BC Extra  |  Company News

Forest, moksha8 in commercialization deal

Forest Laboratories Inc. (NYSE:FRX) granted moksha8 Pharmaceuticals Inc. (Wayne, Pa.) exclusive commercialization rights in Latin America for antidepressant Viibryd vilazodone and potentially other Forest products. Forest, which will pay moksha8 up to $125 million based on milestones over...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >